Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at UC Irvine
- Dates
- study startedestimated completion
- Principal Investigator
- by Amin Alpesh, MD (uci)
Description
Summary
Keywords
Eligibility
Locations
Lead Scientist at UC Health
- Amin Alpesh, MD (uci)
Clinical Professor, Medicine. Authored (or co-authored) 217 research publications.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Rigel Pharmaceuticals
- ID
- NCT04629703
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated